Cardiogen — EU research guide.
Cardiogen is a synthetic tetrapeptide (Ala-Glu-Asp-Arg) from the Khavinson bioregulator series, proposed to support cardiomyocyte metabolism and cardiovascular tissue maintenance. It is studied alongside other organ-specific short peptide bioregulators such as Vesugen (vascular) and Cortagen, which PeptideCompare already tracks.
What is Cardiogen?
Cardiogen is a synthetic tetrapeptide (Ala-Glu-Asp-Arg) from the Khavinson bioregulator series, proposed to support cardiomyocyte metabolism and cardiovascular tissue maintenance. It is studied alongside other organ-specific short peptide bioregulators such as Vesugen (vascular) and Cortagen, which PeptideCompare already tracks.
What does the research show?
Animal and limited human-cohort studies from Eastern European research groups report improved cardiac tissue markers and recovery metrics after experimental cardiac stress. Independent Western replication is minimal, and no peer-reviewed Phase-style human trials are publicly available as of mid-2026.
EU legal status
Not approved as a medicine anywhere in the EU. Available only from specialist research peptide vendors for laboratory research.
Molecular information
Pharmacokinetics
Cardiogen is not yet in our price comparison
We expand EU supplier coverage every month.